Shares of Immatics N.V. (NASDAQ: IMTX) are soaring 5.07% in intraday trading on Tuesday, as the biotechnology company receives positive attention from Wall Street analysts. The stock's upward movement comes on the heels of reaffirmed Buy ratings and an increased price target from prominent research firms.

Mizuho Securities has maintained its Buy rating on Immatics, setting a price target of $23.00. This vote of confidence from Mizuho analyst Graig Suvannavejh, who covers the Healthcare sector, suggests a strong upside potential for the stock. Additionally, Guggenheim has not only reaffirmed its Buy rating but also raised its price target on Immatics to $19 from $16, further bolstering investor sentiment.

These positive analyst actions reflect growing optimism about Immatics' prospects in the biotechnology space. As investors digest these bullish signals from Wall Street, the stock's significant price increase today indicates that the market is responding favorably to the analysts' outlook. Traders and investors will likely continue to monitor Immatics closely for any further developments that could impact its growth trajectory.